Prescient Therapeutics Ltd has released a press release.
September 2019 Appendix 4C - Quarterly
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Prescient Therapeutics
- Appendix 4E and 2019 Annual Report
- June 2019 Appendix 4C - Quarterly
- PTX Initiates Phase 1b Clinical Trial for PTX-100
- Change to Exercise Price of Options
- Canadian Patent Granted for PTX-200
Later from Prescient Therapeutics
- Prescient Ausbiotech Ras Presentation
- Receipt of R&D Tax Rebate
- 1st patient dosed in trial for first in class drug PTX-100
- PTX in new CAR-T collaboration
- Third complete response in PTX-200 AML Trial
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics